Evidence map›Paper›PMID 36820215›Full record

ArticleCase reports in oncology

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report.

Mikako Nakamura, Kaoru Watanabe, Taku Nishimura, Keishi Yoshida, Kento Fukumoto, Noriko Hiyama, Yoshio Masuda, Teppei Morikawa, Jun Matsumoto, Kazuhiro Usui

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Mikako NakamuraDepartment of Respiratory Medicine, NTT Medical Center Tokyo, Tokyo, Japan.
Kaoru WatanabeDepartment of Respiratory Medicine, NTT Medical Center Tokyo, Tokyo, Japan.
Taku NishimuraDepartment of Respiratory Medicine, NTT Medical Center Tokyo, Tokyo, Japan.
Keishi YoshidaDepartment of Respiratory Medicine, NTT Medical Center Tokyo, Tokyo, Japan.
Kento FukumotoDepartment of General Thoracic Surgery, NTT Medical Center Tokyo, Tokyo, Japan.
Noriko HiyamaDepartment of General Thoracic Surgery, NTT Medical Center Tokyo, Tokyo, Japan.
Yoshio MasudaDepartment of Diagnostic Pathology, NTT Medical Center Tokyo, Tokyo, Japan.
Teppei MorikawaDepartment of Diagnostic Pathology, NTT Medical Center Tokyo, Tokyo, Japan.
Jun MatsumotoDepartment of General Thoracic Surgery, NTT Medical Center Tokyo, Tokyo, Japan.
Kazuhiro UsuiDepartment of Respiratory Medicine, NTT Medical Center Tokyo, Tokyo, Japan.
NTT Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary pleural angiosarcoma (PPA) is a rare and clinically fatal pleural tumor originating from vascular endothelial cells. Herein, we presented the case of a 73-year-old man who was referred to our emergency room with complaints of right chest and back pain for a few days. Chest computed tomography revealed massive pleural effusion and a large mass in the right chest cavity. Thoracoscopic examination demonstrated a large hemorrhagic tumor on the parietal pleura whose pathological analysis indicated PPA. The patient received immunotherapy combined with nivolumab and ipilimumab. A cycle of nivolumab and ipilimumab improved his hemorrhagic anemia and reduced the pleural effusion and tumor size. This treatment outcome suggests that nivolumab and ipilimumab comprise a vital treatment option for PPA.

Indexed as

Case reportIpilimumabNivolumabPrimary pleural angiosarcoma

Identifiers

PMID36820215
PMCPMC9938394
OpenAlexW4321181055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.